A series of real stories from real people about their unique experiences along the HIV Continuum of Care.
See more at Positivespin.HIV.gov.
Healthcare providers and consumers need HIV-related drug information and, increasingly, they depend on mobile devices to access that information. AIDSinfo is meeting both needs with the release of the AIDSinfo Drug App. Using data from theAIDSinfo Drug Database, the drug app provides information on more than 100 HIV-related Food and Drug Administration (FDA)-approved and investigational drugs. The AIDSinfo Drug App—provided free from the National Library of Medicine at the National Institutes of Health—is available for iOS and Android devices.
The information on the AIDSinfo Drug App, offered in English and Spanish, is tailored to meet the needs of both healthcare providers and consumers. The app works offline, ensuring that healthcare providers and consumers can access vital drug information anywhere—even in healthcare facilities that may not have an Internet connection.
The AIDSinfo Drug App pulls FDA labels from Daily Med for approved HIV-related drugs. The app also integrates information on drug nomenclature and chemical structure from ChemIDplus. Information from the labels is condensed in easy-to-understand summaries in English and Spanish for consumers.
Users can also access information on HIV-related drugs under investigation via the AIDSinfo Drug App. The investigational drug summaries, which are developed from the latest clinical trial results, are tailored by audience: technical, more detailed summaries for healthcare providers and less complex summaries in English and Spanish for consumers.
Users can also personalize the AIDSinfo Drug App. According to their needs, users can set pill reminders, bookmark drugs, or add personal notes:
Stay tuned as AIDSinfo updates the app with additional features. Visit AIDSinfo to download the drug app to your iOS or Android device. And keep us posted on your experience with the app. We welcome your questions and comments at ContactUs@aidsinfo.nih.gov.
From the Washington Blade…
A new study from the Centers for Disease Control (CDC) found that more than 90 percent of new HIV infections in the U.S. are passed on from HIV-positive people who are not in medical care or treatment, the Journal of the American Medical Association reports.
The study, published Feb. 23, “estimates that 91.5 percent of new HIV infections in 2009 were attributable to people with HIV who were not in medical care, including those who didn’t know they were infected. In comparison, less than six percent of new infections could be attributed to people with HIV who were in care and receiving antiretroviral therapy,” the Journal reports.
“We were shocked to see that the number was as high as it is — nine out of 10 new HIV infections in 2009 occurred this way — over 91.5 percent” said Michael Weinstein, AIDS Healthcare Foundation President. “Such off-the-charts numbers suggest that HIV/AIDS resources, funding and energies must be directed toward far more aggressive and proactive HIV testing, linkage to medical care and antiretroviral treatment for those already infected rather than to the more expensive and esoteric HIV prevention methods such as PrEP. We’ve known for over four years that ‘treatment as prevention’ works. Until this study, we just didn’t know how great the need was for us to fully deploy ‘treatment as prevention’ to get as many HIV-positive individuals in care and on treatment as possible in order to break the chain of infection.”
(Reuters) – Gay men at high risk of HIV who took a daily dose of a Gilead AIDS drug as a preventative measure cut their risk of infection by 86 percent, according to results of a British trial released on Tuesday. Researchers who conducted the trial of so-called pre-exposure prophylaxis (PrEP) said the results offer real hope of reversing the HIV epidemic among men who have sex with men, one of the highest risk groups.
“These results … show PrEP is highly effective at preventing HIV infection in the real world,” said Sheena McCormack, a professor of clinical epidemiology at University College London and the study’s lead investigator.
PrEP involves people who do not have HIV but who are at high risk of becoming infected and seek to protect themselves by taking a single pill, usually a combination of two antiretrovirals, every day.
The Centers for Disease Control and Prevention’s (CDC) annual HIV Surveillance Report titledDiagnoses of HIV Infection in the United States and Dependent Areas, 2013, is now available online [PDF 2.9MB]. The report summarizes information about diagnosed HIV infection from 2009 to 2013 representative of all 50 states, the District of Columbia, and six U.S. dependent areas. Overall, HIV diagnosis rates remain stable yet disparities persist among some groups.
The report shows that the annual rate of diagnosis in the United States remained stable with 15.0 per 100,000 in 2013 compared to 15.3 per 100,000 in 2009.
Despite this, disparities persist—and in some cases—rates have increased among certain groups. As evidenced by this report and other previously released data, gay, bisexual, and other men who have sex with men (MSM); young adults; and racial and ethnic minorities continue to bear the disproportionate burden of HIV…
From the New York Times…
A new compound has blocked H.I.V. infection so well in monkeys that it may be able to function as a vaccine against AIDS, the scientists who designed it reported Wednesday.
H.I.V. has defied more than 30 years of conventional efforts to fashion a vaccine. The new method stimulates muscle cells to produce proteins that somewhat resemble normal antibodies, which have Y-shaped heads. These proteins have both a head and a tail, and they use them to simultaneously block two sites on each “spike” that the virus uses to attach itself to a cell.
If both sites can be blocked on every spike, the virus becomes helpless and drifts off unattached into eventual oblivion by the immune system.
“It’s a twofer,” said Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, which supported the work. “It’s very impressive, and the method is quite promising. But it’s still just in an animal model, so we’ll need to see evidence of whether it works in humans.”
JAMA. 2015;313(7):660. doi:10.1001/jama.2015.238
People living with HIV infection have a high incidence of AIDS-related cancers—Kaposi sarcoma, non-Hodgkin lymphoma, and cervical cancer—and they’re at increased risk for other cancers as well. Yet only 41% of cancer survivors have been tested for HIV, including nearly half of patients with AIDS-related cancers. Clinicians should know a cancer patient’s HIV serostatus to improve cancer outcomes, reduce mortality, and identify secondary cancers that may result from co-infections with hepatitis B and C and Epstein-Barr virus.